Lincocin (Lincomycin)

Lincomycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. This binding blocks the translocation step of peptide chain elongation, resulting in a bacteriostatic effect that limits the growth of susceptible Gram‑positive organisms.

The appropriate dose of Lincocin is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and other clinical factors. Dosage regimens are individualized and should follow the prescriber’s instructions.

Safety data for lincomycin in pregnancy and lactation are limited. Use is generally reserved for situations where the potential benefit outweighs potential risks. Clinicians should evaluate each case carefully and discuss possible effects with the patient.

To order Lincocin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Lincocin (lincomycin) belongs to the lincosamide class, similar to clindamycin. Both share a comparable mechanism of inhibiting protein synthesis, but lincomycin is often chosen when clindamycin resistance is a concern or when a specific formulation is needed. Clinical efficacy and safety profiles are generally alike, though individual patient factors may guide selection.

Lincocin should be stored at 2‑8 °C, kept refrigerated, protected from light, and never frozen. Before use, inspect the solution for particulate matter or discoloration. Follow aseptic techniques when preparing for intramuscular or intravenous administration.

Lincocin is supplied as an injectable solution for intramuscular or intravenous administration. The route, infusion rate, and duration are determined by the prescribing clinician and should be performed by qualified healthcare personnel in an appropriate clinical setting.

Serious risks include Clostridioides difficile‑associated diarrhea, which can cause severe colitis, anaphylactic reactions that require immediate medical attention, and rare cases of severe neutropenia that increase susceptibility to secondary infections. Patients should be monitored closely for these events.

Lincocin is contraindicated in individuals with a known hypersensitivity to lincomycin, other lincosamides, or any component of the formulation. Caution is also advised for patients with severe renal or hepatic impairment, and it should be avoided in pregnancy unless the benefit justifies the potential risk.